局部给药市场机会、成长动力、产业趋势分析及 2025 - 2034 年预测

2024 年全球局部给药市场价值为 1,563 亿美元，预计到 2034 年将以 8.8% 的复合年增长率成长，达到 3,623 亿美元。这一增长主要得益于人们对非侵入性治疗方法的日益青睐，以及局部和全身性治疗中局部用药产品的广泛使用。局部给药依赖于透过皮肤或黏膜给药活性药物成分，这是一种方便有效的针对特定区域给药的方法，无需口服或註射。随着製剂技术的进步，这些给药系统现在涵盖凝胶、喷雾剂、贴片、软膏和乳霜等各种应用，每种应用都旨在最大限度地提高药物吸收并增强治疗效果。随着全球医疗保健趋势转向家庭自我照护和慢性病管理，对外用解决方案的需求持续激增，尤其是在寻求易于使用和副作用最小的患者群体中。

市场按产品类型细分为液体製剂、半固体製剂、固体製剂及透皮产品。半固体製剂占最大市场份额，占2024年市场总收入的62.1%。此细分市场包含乳膏、乳液、软膏、糊剂和凝胶等多个子类别，常用于治疗各种皮肤病和发炎。液体製剂（包括混悬液和溶液）以及固体製剂（包括粉剂和栓剂）也越来越受欢迎。同时，透皮产品分为贴片和半固体类型，可提供控释药物并增强患者遵从性。

痤疮、湿疹、牛皮癣和皮肤炎等皮肤相关疾病的普遍存在，促使人们寻求有效的治疗方法，尤其是那些易于涂抹且能够精准缓解症状的治疗方法。随着这些慢性皮肤问题在全球持续增长，对半固体外用溶液的需求也显着增长。半固体外用溶液的实用优势以及快速、局部缓解症状的能力，使其成为医护人员和患者的首选。

就给药途径而言，2024年，经皮给药占市场领先地位，收入份额达58.7%。顽固性皮肤病的盛行推动了经皮给药的应用，这种技术允许患者直接治疗患处。由于其操作简便且能有效控制长期症状，因此这种方法正日益受到欢迎。患者越来越倾向于自行给药、无需医疗监督即可在家中轻鬆进行的非手术治疗，这有利于进一步扩大市场。

终端用途细分显示，家庭护理领域创造了最高收入，到2024年将达到669亿美元。该领域的成长得益于人们对需要持续管理的慢性疾病便捷治疗方案日益增长的需求。局部疗法提供了一种比口服或註射药物更安全、更简单的替代方案，而口服或註射药物通常需要专业人士的协助。随着医疗保健系统持续强调门诊护理和居家治疗方案，局部给药系统的使用预计将会扩大。

从地区来看，美国市场表现突出，预计其市场规模将从2023年的591亿美元成长至2034年的1,490亿美元。强劲成长的动力源于消费者认知度的提升、医疗保健支出的增加以及美国全国范围内沉重的皮肤病负担。此外，广泛的外用产品供应以及对创新药物输送技术不断增长的投资也巩固了该地区的主导地位。

全球局部给药领域竞争激烈，跨国公司和小型企业都参与其中。各大公司正加大投资，开发先进的给药系统，例如微针技术、智慧穿戴装置和奈米技术驱动的平台。这些创新旨在提高药效、延长释放时间并提升患者舒适度。此外，製药商与医疗研究机构之间的合作正成为加速尖端疗法应用策略的关键组成部分。监管支持，包括简化的专利流程和更快的药品审批，正在进一步鼓励创新，并加剧这个快速发展的市场的竞争。

目录

第一章：方法论与范围

第二章：执行摘要

第三章：行业洞察

• 产业生态系统分析
• 产业衝击力
  • 成长动力
    • 皮肤病和慢性病盛行率上升
    • 配方技术的进步
    • 自我治疗的需求不断增长
  • 产业陷阱与挑战
    • 皮肤刺激和渗透性有限
    • 监管挑战
• 成长潜力分析
• 监管格局
• 川普政府关税
  • 对贸易的影响
    • 贸易量中断
    • 报復措施
  • 对产业的影响
    • 供应方影响（原料）
      • 主要材料价格波动
      • 供应链重组
      • 生产成本影响
    • 需求面影响（售价）
      • 价格传导至终端市场
      • 市占率动态
      • 消费者反应模式
  • 受影响的主要公司
  • 策略产业反应
    • 供应链重组
    • 定价和产品策略
    • 政策参与
  • 展望与未来考虑
• 技术格局
• 未来市场趋势
• 差距分析
• 波特的分析
• PESTEL分析

第四章：竞争格局

• 介绍
• 公司市占率分析
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 策略仪表板

第五章：市场估计与预测：按产品，2021 - 2034 年

• 主要趋势
• 半固体製剂
  • 乳霜
  • 软膏
  • 乳液
  • 凝胶
  • 糊状物
• 液体製剂
  • 暂停
  • 解决方案
• 固体製剂
  • 粉末
  • 栓剂
• 透皮产品
  • 透皮贴剂
  • 透皮半固体

第六章：市场估计与预测：按管理路线，2021 - 2034 年

• 主要趋势
• 皮肤给药
• 眼科药物输送
• 直肠给药
• 阴道给药
• 鼻腔给药

第七章：市场估计与预测：依最终用途，2021 - 2034 年

• 主要趋势
• 居家照护环境
• 医院和诊所
• 烧伤中心
• 其他最终用途

第八章：市场估计与预测：按地区，2021 - 2034 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第九章：公司简介

• AbbVie
• Bausch Health Companies
• Bayer
• Cipla
• Eli Lilly and Company
• Galderma Laboratories
• GlaxoSmithKline
• Johnson & Johnson
• Merck
• Novartis International
• Pfizer
• Sanofi
• Sun Pharmaceutical Industries
• Taro Pharmaceutical Industries
• Teva Pharmaceutical Industries
• Viatris

The Global Topical Drug Delivery Market was valued at USD 156.3 billion in 2024 and is estimated to grow at a CAGR of 8.8% to reach USD 362.3 billion by 2034. This growth is largely driven by the increasing preference for non-invasive treatment methods and the widespread use of topical products for localized and systemic therapies. Topical drug delivery relies on administering active pharmaceutical ingredients through the skin or mucous membranes, offering a convenient and effective way to target specific areas without the need for oral ingestion or injections. With advancements in formulation technologies, these delivery systems now include a wide variety of applications such as gels, sprays, patches, ointments, and creams, each designed to maximize drug absorption and enhance therapeutic outcomes. As global healthcare trends shift towards self-care and chronic disease management at home, the demand for topical solutions continues to surge, particularly among patients seeking ease of use and minimal side effects.

The market is segmented by product type into liquid formulations, semi-solid formulations, solid formulations, and transdermal products. Semi-solid formulations held the largest market share, accounting for 62.1% of the total market revenue in 2024. This segment includes various subcategories such as creams, lotions, ointments, pastes, and gels, which are commonly used to treat a wide range of skin disorders and inflammatory conditions. Liquid formulations, which include suspensions and solutions, and solid formulations, comprising powders and suppositories, are also gaining traction. Meanwhile, transdermal products are split into patches and semi-solid types, offering controlled drug release and enhanced patient compliance.

The widespread occurrence of skin-related conditions such as acne, eczema, psoriasis, and dermatitis is fueling the need for effective treatment options, particularly those that are easy to apply and deliver targeted relief. As these chronic skin problems continue to rise globally, the demand for semi-solid topical solutions has grown significantly. Their practical benefits and ability to provide quick, localized relief make them a favored choice among both healthcare providers and patients.

In terms of delivery route, dermal drug delivery led the market with a revenue share of 58.7% in 2024. The prevalence of persistent skin conditions has pushed the adoption of dermal applications, which allow patients to treat affected areas directly. This approach is gaining popularity due to its user-friendly nature and effectiveness in managing long-term symptoms. Patients are increasingly leaning toward self-administered, non-surgical treatments that can be easily used in home settings without medical supervision, which supports further market expansion.

End-use segmentation shows that home care settings generated the highest revenue, reaching USD 66.9 billion in 2024. This segment's growth is supported by the rising need for convenient treatment solutions for chronic illnesses that require ongoing management. Topical therapies offer a safer, simpler alternative to oral or injectable medications, which often require professional assistance. As healthcare systems continue to emphasize outpatient care and home-based treatment options, the use of topical drug delivery systems is expected to expand.

Regionally, the U.S. market stood out, with values projected to grow from USD 59.1 billion in 2023 to an estimated USD 149 billion by 2034. This strong growth is fueled by high consumer awareness, increased healthcare spending, and a significant burden of dermatological conditions across the country. The accessibility of a wide range of topical products and growing investment in innovative drug delivery technologies also contribute to the region's dominance.

The global topical drug delivery landscape is highly competitive, with participation from both multinational corporations and smaller firms. Companies are channeling investments into developing advanced delivery systems such as microneedle technologies, smart wearables, and nanotechnology-driven platforms. These innovations aim to improve drug efficacy, extend release profiles, and enhance patient comfort. Additionally, partnerships between pharmaceutical manufacturers and healthcare research institutions are becoming a crucial part of the strategy to accelerate the adoption of cutting-edge therapies. Regulatory support, including simplified patent processes and faster drug approvals, is further encouraging innovation and intensifying competition in this rapidly evolving market.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of skin and chronic diseases
    • 3.2.1.2 Advancements in formulation technologies
    • 3.2.1.3 Growing demand for self-administered treatments
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Skin irritation and limited permeability
    • 3.2.2.2 Regulatory challenges
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Trump administration tariffs
  • 3.5.1 Impact on trade
    • 3.5.1.1 Trade volume disruptions
    • 3.5.1.2 Retaliatory measures
  • 3.5.2 Impact on the Industry
    • 3.5.2.1 Supply-side impact (raw materials)
      • 3.5.2.1.1 Price volatility in key materials
      • 3.5.2.1.2 Supply chain restructuring
      • 3.5.2.1.3 Production cost implications
    • 3.5.2.2 Demand-side impact (selling price)
      • 3.5.2.2.1 Price transmission to end markets
      • 3.5.2.2.2 Market share dynamics
      • 3.5.2.2.3 Consumer response patterns
  • 3.5.3 Key companies impacted
  • 3.5.4 Strategic industry responses
    • 3.5.4.1 Supply chain reconfiguration
    • 3.5.4.2 Pricing and product strategies
    • 3.5.4.3 Policy engagement
  • 3.5.5 Outlook and future considerations
• 3.6 Technological landscape
• 3.7 Future market trends
• 3.8 Gap analysis
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Semi-solid formulations
  • 5.2.1 Creams
  • 5.2.2 Ointments
  • 5.2.3 Lotions
  • 5.2.4 Gel
  • 5.2.5 Pastes
• 5.3 Liquid formulations
  • 5.3.1 Suspensions
  • 5.3.2 Solutions
• 5.4 Solid formulations
  • 5.4.1 Powders
  • 5.4.2 Suppositories
• 5.5 Transdermal products
  • 5.5.1 Transdermal patches
  • 5.5.2 Transdermal semi-solids

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Dermal drug delivery
• 6.3 Ophthalmic drug delivery
• 6.4 Rectal drug delivery
• 6.5 Vaginal drug delivery
• 6.6 Nasal drug delivery

Chapter 7 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Home care settings
• 7.3 Hospitals and clinics
• 7.4 Burn centers
• 7.5 Other end use

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 AbbVie
• 9.2 Bausch Health Companies
• 9.3 Bayer
• 9.4 Cipla
• 9.5 Eli Lilly and Company
• 9.6 Galderma Laboratories
• 9.7 GlaxoSmithKline
• 9.8 Johnson & Johnson
• 9.9 Merck
• 9.10 Novartis International
• 9.11 Pfizer
• 9.12 Sanofi
• 9.13 Sun Pharmaceutical Industries
• 9.14 Taro Pharmaceutical Industries
• 9.15 Teva Pharmaceutical Industries
• 9.16 Viatris